• 3
Reading Time: 5 minutes

Severe diabetic foot ulcers that fail months of standard care remain a leading cause of major lower-limb amputation. When an ulcer is large, deep, and poorly perfused, debridement, offloading, infection control, and revascularization may not be enough. Over the past decade, surgeons in China have reported results with an unusual approach performed not on the foot but on the shin bone. Known as tibial cortex transverse transport (TTT), it borrows principles from limb-lengthening surgery to stimulate new blood vessel growth in the lower leg.

What the Procedure Involves

TTT is based on distraction osteogenesis: slowly pulling living bone apart stimulates new bone and new blood vessels in the surrounding tissue. The surgeon cuts a rectangular window of cortical bone from the inner surface of the upper tibia and attaches it to an external fixator. The window is moved outward by roughly a millimetre per day for about two weeks, then returned. The ulcer is still debrided and treated in the usual way. Early techniques used a window about 5 cm long; modified techniques use smaller openings to reduce tibial complications (Liu J et al., 2024).

Proposed Mechanism

In diabetic rat models with induced limb ischemia, TTT increased vessel volume, perfusion, and circulating endothelial progenitor cells compared with sham surgery, with higher levels of hypoxia-inducible factor-1α (HIF-1α), SDF-1, and VEGF, and a shift of macrophages toward the anti-inflammatory M2 type (Qin et al., 2024; Liu J et al., J Inflamm Res, 2024). These findings suggest a plausible mechanism, but rats do not reproduce the neuropathy, chronic infection, and long-standing vascular disease of human diabetic foot ulcers.

What the Clinical Studies Report

The foundational comparative study

Chen and colleagues (2020) compared 136 patients treated with TTT against 137 historical controls who received standard surgical care. All had University of Texas grade 2B–3D ulcers unresponsive to at least six months of treatment, with a mean area of 44 cm². At two years, 96% of TTT ulcers had healed versus 68% of controls; major amputation occurred in 2.9% versus 23%, and recurrence in 2.9% versus 17%. The authors stated that randomized trials are needed to confirm these findings.

Pooled evidence

A 2023 meta-analysis of seven studies (818 participants, 661 treated with TTT) found a pooled healing rate of 96% and limb salvage rate of 98% (Hu et al., 2023). Compared with non-TTT treatment, TTT was associated with higher odds of healing (odds ratio 10.43) and limb salvage (odds ratio 9.65), and lower recurrence (risk ratio 0.18). None of the included studies was a fully randomized trial, and all came from China.

More recent series

A retrospective series of 98 patients treated with a small-window technique reported 95.8% healing, with a mean healing time of about 53 days (Liu J et al., Front Endocrinol, 2024). A retrospective comparison of 60 patients with Wagner grade 3 or higher ulcers found higher healing (96.7% vs 80%), fewer amputations (3.3% vs 20%), and less recurrence (6.7% vs 26.7%) with TTT than with platelet-rich plasma dressings over 18 months (Zhen et al., 2025).

Complications and Limitations

TTT is an invasive procedure on otherwise healthy bone. In the meta-analysis, tibial fracture occurred in about 2% of patients and pin-site infection in about 8%; skin necrosis over the tibia has also been described (Hu et al., 2023). In the 98-patient series, 8.2% had a complication, including two perioperative deaths, reflecting the high baseline surgical risk of this population.

Most studies are retrospective, come from a small number of centres, use non-randomized or historical comparison groups, and have variable follow-up. Researchers have also noted that the procedure may be less effective when major arteries supplying the ankle are severely or completely blocked, so it does not replace assessment and treatment of peripheral artery disease.

Key Takeaways

Tibial cortex transverse transport applies distraction osteogenesis to the tibia to stimulate angiogenesis and support healing of severe, non-healing diabetic foot ulcers. Published studies report healing rates around 95% with low amputation and recurrence rates, and animal research points to HIF-1α-mediated vessel growth as a possible mechanism. These results come from non-randomized studies with important risks of bias, and the procedure carries its own complications. Randomized controlled trials in diverse populations are needed to define its place alongside offloading, debridement, infection management, and revascularization.

References

  • Chen Y, Kuang X, Zhou J, et al. Proximal tibial cortex transverse distraction facilitating healing and limb salvage in severe and recalcitrant diabetic foot ulcers. Clinical Orthopaedics and Related Research. 2020;478(4):836–851.
  • Hu X, Xiu Z, Li G, et al. Effectiveness of transverse tibial bone transport in treatment of diabetic foot ulcer: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;13:1095361.
  • Liu J, Yao X, Xu Z, et al. Modified tibial cortex transverse transport for diabetic foot ulcers with Wagner grade ≥ II: a study of 98 patients. Frontiers in Endocrinology. 2024;15:1334414.
  • Liu J, Huang X, Su H, et al. Tibial cortex transverse transport facilitates severe diabetic foot wound healing via HIF-1α-induced angiogenesis. Journal of Inflammation Research. 2024;17:2681–2696.
  • Qin W, Liu K, Su H, et al. Tibial cortex transverse transport promotes ischemic diabetic foot ulcer healing via enhanced angiogenesis and inflammation modulation in a novel rat model. European Journal of Medical Research. 2024;29:155.
  • Zhen PX, Su HJ, Yang SJ, et al. Comparison of clinical efficacy between tibial cortex transverse transport and platelet-rich plasma treatment for severe diabetic foot ulcers. Frontiers in Surgery. 2025;12:1507982.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.